Skip to content

Real-World Experience of Patients Treated for Musculoskeletal Injuries With SAM in Routine Care

Customer Survey of Athletic Trainers Who Utilize SAM Ultrasound Device in Routine Care

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05254470
Enrollment
135
Registered
2022-02-24
Start date
2020-09-01
Completion date
2022-02-01
Last updated
2022-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Musculoskeletal Injury, Pain, Chronic, Pain, Acute, Sport Injury, Soft Tissue Injuries, Arm Injury, Back Pain, Tendon Injuries, Muscle Injury

Keywords

Continuous Ultrasound, Sustained Acoustic Medicine, Musculoskeletal Injuries, Low Intensity Contiguous Ultrasound, Pain, Soft Tissue Injury

Brief summary

The purpose of this study is to evaluate continuous ultrasound treatment with diclofenac coupling patch during routine care of musculoskeletal injuries which failed conservative treatment to better understand clinical utilization of the treatment on types of injuries, how the treatment helps patients (pain, function and quality of life), and information on healthcare provider ordering the therapy and general workflow. Low-intensity continuous ultrasound (LICUS) is a bio regenerative technology used when normal rehabilitation is insufficient, applied with a wearable device (SAM, Zetroz Systems LLC) for daily use. The treatment provides long-duration ultrasound for approximately four hours. The objective of this study is to examine the real-world outcome data on symptoms improvement and return to function using SAM during routine care.

Detailed description

ZetrOZ's SAM Ultrasound Device is a portable and wearable medical device which, when applied to various areas of the body, applies Low Intensity Therapeutic Ultrasound to deep tissues. The SAM device is currently used by a broad range of Athletic Trainers (ATs) in the United States to assist in the rehabilitation of injured athletes. The purpose of this this study is to examine the real-world outcome data on symptoms improvement and return to function using SAM during routine care. This includes understanding utilization of the treatment (how often and how much time), how the treatment helps patients (rehabilitation and recovery), and information on SAM treatment augmenting conservative therapies.

Interventions

3MHz, 0.132W/cm2, 1.3W for 4 hours day delivered by an acoustic device

Sponsors

ZetrOZ, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Work-related musculoskeletal injuries with limited improvement under traditional therapies

Exclusion criteria

* Healthy participant

Design outcomes

Primary

MeasureTime frameDescription
Numeric Pain Rating Scale (NRS) (0-10)0 - 4 weeksChange in pain severity over the time of treatment, 0 being lowest, and 10 being the worst pain.

Secondary

MeasureTime frameDescription
Global Health Improvement Score (GROC) (-7 to +7)0 - 4 weeksQuality of health care improvement satisfaction from intervention compared to conservative treatment

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026